Fukumoto H, Nishio M, Nishio K, Heike Y, Arioka H, Kurokawa H, Ishida T, Fukuoka K, Nomoto T, Ohe Y, Saijo N
Pharmacology Division, National Cancer Center Research Institute, Tokyo.
Jpn J Cancer Res. 1997 May;88(5):501-5. doi: 10.1111/j.1349-7006.1997.tb00409.x.
To investigate the immunoregulatory effect of murine interferon-gamma-inducing factor (mIGIF), we transfected Lewis lung carcinoma (LLC) cells with a mammalian expression vector containing the mIGIF complementary DNA. The culture medium of the transfectant cells stimulated interferon-gamma (IFN-gamma) production by spleen cells in vitro in the presence of anti-CD3 antibody and markedly potentiated the effect of interleukin-12 (IL-12) on IFN-gamma production by spleen cells. mIGIF transfectant cells showed reduction of tumorigenicity and induction of an in vivo immuno-protective effect against the parental LLC cells. To examine the combined effect of systemic administration of recombinant IL-12 (rIL-12) and local mIGIF on the tumorigenicity, mice were challenged with LLC or transfectant cells on day 0, and the tumor-bearing mice were injected with 50 ng of rIL-12 intraperitoneally from day 7 to 11. Systemic rIL-12 showed an anti-tumor effect. However, mIGIF gene expression did not potentiate this effect of systemic rIL-12 in vivo.
为了研究小鼠γ-干扰素诱导因子（mIGIF）的免疫调节作用，我们用含有mIGIF互补DNA的哺乳动物表达载体转染Lewis肺癌（LLC）细胞。在抗CD3抗体存在的情况下，转染细胞的培养基在体外刺激脾细胞产生γ-干扰素（IFN-γ），并显著增强白细胞介素-12（IL-12）对脾细胞产生IFN-γ的作用。mIGIF转染细胞显示出致瘤性降低，并诱导了对亲本LLC细胞的体内免疫保护作用。为了检测重组IL-12（rIL-12）全身给药与局部mIGIF对致瘤性的联合作用，在第0天用LLC或转染细胞攻击小鼠，从第7天到第11天给荷瘤小鼠腹腔注射50 ng rIL-12。全身给予rIL-12显示出抗肿瘤作用。然而，mIGIF基因表达在体内并未增强全身rIL-12的这种作用。
